Adelaide Research & Scholarship
Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/89454
| Type: | Conference item |
| Title: | Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepoint |
| Author: | Branford, S. Ross, D. Yeung, D. Braley, J. Hughes, T. |
| Citation: | Blood, 2014, vol.124, iss.21, pp.4561-4561 |
| Publisher: | American Society of Hematology |
| Issue Date: | 2014 |
| ISSN: | 0006-4971 1528-0020 |
| Conference Name: | 56th ASH Annual Meeting (6 Dec 2014 - 9 Dec 2014 : San Francisco, California) |
| Statement of Responsibility: | Susan Branford, David M Ross, David T Yeung, Jodi Braley, and Timothy P. Hughes |
| Rights: | © 2014 by The American Society of Hematology |
| Published version: | http://www.bloodjournal.org/content/124/21/4561 |
| Appears in Collections: | Aurora harvest 2 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.